Dabigatran Etexilate
75 mg · Capsule
- Prescription only
- Direct Thrombin Inhibitor
- Active substance
- Dabigatran Etexilate
- Used in
- Blood, clotting and anaemia
- Made by
- Dr.Reddys Laboratories Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (DABIGATRAN). It describes the substance, not this exact product.
Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors.
Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus.
Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and dabigatran have similar pharmacological activity.
Dabigatran is eliminated primarily in the urine.
Coadministration of dabigatran with a high-fat meal delays the time to C max by approximately 2 hours but has no effect on the bioavailability of dabigatran; Dabigatran may be administered with or without food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-13
Safety of the active substance
From the US prescribing label for the same active substance (DABIGATRAN). It describes the substance, not this exact product.
WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including dabigatran, increases the risk of thrombotic events.
- Dabigatran is contraindicated in patients with:.
- Active pathological bleeding [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )].
- History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions ( 6.1 )].
- Mechanical prosthetic heart valve [see Warnings and Precautions ( 5.4 )].
The most frequent adverse reactions leading to discontinuation of dabigatran etexilate capsules were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
Bulgaria4 matching products
European UnionNo exact match for this strength and form
Details
| Made by | Dr.Reddys Laboratories Inc |
|---|---|
| Active substance | Dabigatran Etexilate |
| Used in | Blood, clotting and anaemia |
| Strength | 75 mg |
| Form | Capsule |
| Route | Oral |
| Packs | 60 CAPSULE in 1 BOTTLE |
| NDC | 43598-642 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
31 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Capsule23 products
75 mg8
75 mg · 8 companies
- Capsule, Coated Pellets8 products
75 mg3
75 mg · 3 companies
110 mg2
110 mg · 2 companies
150 mg3
150 mg · 3 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.